Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer.
Alopecia
breast cancer
hormonal therapy
Journal
Exploration of targeted anti-tumor therapy
ISSN: 2692-3114
Titre abrégé: Explor Target Antitumor Ther
Pays: United States
ID NLM: 101770662
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
06
2021
accepted:
12
10
2021
entrez:
1
9
2022
pubmed:
1
1
2021
medline:
1
1
2021
Statut:
ppublish
Résumé
Adjuvant hormonal therapy is one of the most important treatments of hormone-receptor-positive breast cancer and includes selective estrogen receptor modulators, aromatase inhibitors, and luteinizing hormone-releasing hormone analogs. In patients receiving these drugs, a progressive recession of frontal-temporal hairlines is often observed, such as a certain grade of hair miniaturization in the same areas and the central scalp area, producing a pseudo-female androgenic alopecia, which has to be considered oncotherapy-induced alopecia. The aim of this work, is to describe the clinical aspects and pathogenesis of this type of alopecia and to analyze the different drugs which have been proposed until now. The authors concude that topical hormones should not be considered as a therapeutic approach because of their direct or indirect oncogenic potential. A therapeutic approach that could be both safe and effective is proposed.
Identifiants
pubmed: 36045704
doi: 10.37349/etat.2021.00059
pii: etat-02-100259
pmc: PMC9400690
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
490-495Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Endocr Rev. 2006 Oct;27(6):677-706
pubmed: 16877675
JAMA Dermatol. 2018 Jun 1;154(6):670-675
pubmed: 29641806
J Investig Dermatol Symp Proc. 2003 Jun;8(1):24-7
pubmed: 12894991
Br J Dermatol. 2009 Aug;161(2):289-94
pubmed: 19438456
Lancet. 2005 May 14-20;365(9472):1687-717
pubmed: 15894097
Ann Oncol. 2013 Jun;24(6):1710-1
pubmed: 23696617
Asia Pac J Oncol Nurs. 2018 Jul-Sep;5(3):262-269
pubmed: 29963588
Ann Intern Med. 2001 Jun 19;134(12):1154-5
pubmed: 11412069
Dermatol Ther. 2016 Nov;29(6):424-432
pubmed: 27424565
Int J Mol Sci. 2021 Jul 22;22(15):
pubmed: 34360578
Med Hypotheses. 2014 Apr;82(4):428-32
pubmed: 24548754
Ann Intern Med. 1997 May 1;126(9):745-6
pubmed: 9139575
BMJ. 1997 Feb 15;314(7079):481
pubmed: 9056798
Oncologist. 2013;18(10):1126-34
pubmed: 24037977
J Dermatolog Treat. 2018 Mar;29(2):149-151
pubmed: 28604133
J Clin Oncol. 2005 Jan 20;23(3):619-29
pubmed: 15545664
J Oncol Pharm Pract. 2021 Mar;27(2):460-463
pubmed: 32529951
Exp Dermatol. 2002 Aug;11(4):376-80
pubmed: 12190948
Br J Dermatol. 2015;172(5):1384-94
pubmed: 25296533
Ann Dermatol. 2014 Dec;26(6):743-6
pubmed: 25473228
J Dermatol. 2012 Dec;39(12):1060-1
pubmed: 22900892
Dermatol Pract Concept. 2020 Jun 29;10(3):e2020074
pubmed: 32642317